WO2001016355A3 - In-vitro-testsystem für gamma-sekretase aus angereicherten-membranen - Google Patents

In-vitro-testsystem für gamma-sekretase aus angereicherten-membranen Download PDF

Info

Publication number
WO2001016355A3
WO2001016355A3 PCT/EP2000/008340 EP0008340W WO0116355A3 WO 2001016355 A3 WO2001016355 A3 WO 2001016355A3 EP 0008340 W EP0008340 W EP 0008340W WO 0116355 A3 WO0116355 A3 WO 0116355A3
Authority
WO
WIPO (PCT)
Prior art keywords
secretase
gamma
test system
vitro test
substances
Prior art date
Application number
PCT/EP2000/008340
Other languages
English (en)
French (fr)
Other versions
WO2001016355A2 (de
Inventor
Katja Fechteler
Klaus Fuchs
Marcus Kostka
Original Assignee
Boehringer Ingelheim Pharma
Katja Fechteler
Klaus Fuchs
Marcus Kostka
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma, Katja Fechteler, Klaus Fuchs, Marcus Kostka filed Critical Boehringer Ingelheim Pharma
Priority to EP00962393A priority Critical patent/EP1212454A2/de
Priority to JP2001520900A priority patent/JP2003508058A/ja
Priority to CA002381952A priority patent/CA2381952A1/en
Priority to MXPA02001754A priority patent/MXPA02001754A/es
Publication of WO2001016355A2 publication Critical patent/WO2001016355A2/de
Publication of WO2001016355A3 publication Critical patent/WO2001016355A3/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96472—Aspartic endopeptidases (3.4.23)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Die vorliegende Erfindung liegt im Feld der Verfahren zum Auffinden von spezifischen η-Sekretase Inhibitoren, die zur Behandlung von neurodegenerativen Erkrankungen eingesetzt werden können, insbesondere von Verfahren, die in vitro durchgeführt werden können. Ferner betrifft diese Erfindung einen Testkit, mit dem das erfindungsgemässe Verfahren durchgeführt werden kann, sowie die Verwendung dieses Testkits oder des Verfahrens zum Auffinden von Substanzen, die spezifisch η-Sekretase inhibieren. Eine weitere Ausführungsform betrifft die Verwendung dieser Substanzen zur Herstellung eines Medikaments zur Behandlung neurodegenerativer Erkrankungen und pharmazeutische Formulierungen, die diese Substanzen enthalten.
PCT/EP2000/008340 1999-08-28 2000-08-25 In-vitro-testsystem für gamma-sekretase aus angereicherten-membranen WO2001016355A2 (de)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP00962393A EP1212454A2 (de) 1999-08-28 2000-08-25 In-vitro-testsytem für gamma-sekretase aus angereicherten-membranen
JP2001520900A JP2003508058A (ja) 1999-08-28 2000-08-25 γ−セクレターゼインビトロテストシステム
CA002381952A CA2381952A1 (en) 1999-08-28 2000-08-25 .gamma.-secretase in vitro test system
MXPA02001754A MXPA02001754A (es) 1999-08-28 2000-08-25 Sistema de ensayo in vitro de gama-secretasa.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19941039.9 1999-08-28
DE1999141039 DE19941039A1 (de) 1999-08-28 1999-08-28 gamma-Sekretase in vitro Testsystem

Publications (2)

Publication Number Publication Date
WO2001016355A2 WO2001016355A2 (de) 2001-03-08
WO2001016355A3 true WO2001016355A3 (de) 2001-08-30

Family

ID=7920037

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/008340 WO2001016355A2 (de) 1999-08-28 2000-08-25 In-vitro-testsystem für gamma-sekretase aus angereicherten-membranen

Country Status (6)

Country Link
EP (1) EP1212454A2 (de)
JP (1) JP2003508058A (de)
CA (1) CA2381952A1 (de)
DE (1) DE19941039A1 (de)
MX (1) MXPA02001754A (de)
WO (1) WO2001016355A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10000161A1 (de) * 2000-01-06 2001-07-19 Boehringer Ingelheim Pharma Verfahren zur Identifikation eines Proteaseinhibitors
MXPA02009756A (es) 2000-04-03 2003-06-17 Bristol Myers Squibb Co Aislamiento de complejo de proteina de gamma-secretasa funcionalmente activa y metodos de deteccion de la actividad e inhibidores de la misma.
DE60123074T3 (de) * 2000-05-11 2015-01-29 Scios Inc. Modulation von gamma-secretase aktivität
DE10131899A1 (de) * 2001-07-04 2003-02-27 Boehringer Ingelheim Pharma In vitro-Screening-Assay für gamma-Secretase
WO2005031363A1 (en) * 2003-09-24 2005-04-07 University Of Chicago Membrane preparation from pichia pastoris to assay ϝ-secretase activity
DK1713501T3 (da) * 2004-01-29 2008-05-26 Cellzome Ag Behandling af neurodegenerative sygdomme ved anvendelse af GPR49
US20070280927A1 (en) * 2004-01-29 2007-12-06 Cellzome Ag Treatment Of Neurodegenerative Diseases By The Use Of Atp7a

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0778266A1 (de) * 1995-12-05 1997-06-11 Bristol-Myers Squibb Company 5-Amino-6-Cyclohexyl-4-Hydroxy-Hexanamid-Derivate als Inhibitoren der Bildung von Beta-Amyloid-Protein
WO1997028261A1 (en) * 1996-01-31 1997-08-07 The Regents Of The University Of California Tandem fluorescent protein constructs
WO1997041443A2 (en) * 1996-04-26 1997-11-06 Smithkline Beecham Plc Method for screening compounds
WO1998015828A1 (en) * 1996-10-07 1998-04-16 Scios Inc. Method to identify direct inhibitors of the beta-amyloid forming enzyme gamma-secretase

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040885A2 (en) * 1995-06-07 1996-12-19 Athena Neurosciences, Inc. β-SECRETASE, ANTIBODIES TO β-SECRETASE, AND ASSAYS FOR DETECTING β-SECRETASE INHIBITION
DE19641180A1 (de) * 1996-09-24 1998-03-26 Schering Ag Verfahren zur Darstellung von APP-Sekretase Modulation und deren Verwendung als Mittel zur Behandlung der Alzheimer'schen Erkrankung
WO1998021589A1 (en) * 1996-11-15 1998-05-22 The Trustees Of The University Of Pennsylvania Screening for modulators of amyloid processing

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0778266A1 (de) * 1995-12-05 1997-06-11 Bristol-Myers Squibb Company 5-Amino-6-Cyclohexyl-4-Hydroxy-Hexanamid-Derivate als Inhibitoren der Bildung von Beta-Amyloid-Protein
WO1997028261A1 (en) * 1996-01-31 1997-08-07 The Regents Of The University Of California Tandem fluorescent protein constructs
WO1997041443A2 (en) * 1996-04-26 1997-11-06 Smithkline Beecham Plc Method for screening compounds
WO1998015828A1 (en) * 1996-10-07 1998-04-16 Scios Inc. Method to identify direct inhibitors of the beta-amyloid forming enzyme gamma-secretase

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KUENTZEL SANDRA L ET AL: "The Alzheimer beta-amyloid protein precursor/protease nexin-II is cleaved by secretase in a trans-Golgi secretory compartment in human neuroglioma cells.", BIOCHEMICAL JOURNAL, vol. 295, no. 2, 1993, pages 367 - 378, XP000986602, ISSN: 0264-6021 *
LI YUE-MING ET AL: "Presenilin 1 is linked with gamma-secretase activity in the detergent solubilized state.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 97, no. 11, 23 May 2000 (2000-05-23), May 23, 2000, pages 6138 - 6143, XP002159974, ISSN: 0027-8424 *
SHOJI M ET AL: "PRODUCTION OF THE ALZHEIMER AMYLOID BETA PROTEIN BY NORMAL PROTEOLYTIC PROCESSING", SCIENCE,US,AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, vol. 258, 2 October 1992 (1992-10-02), pages 126 - 129, XP000616170, ISSN: 0036-8075 *

Also Published As

Publication number Publication date
MXPA02001754A (es) 2002-10-23
DE19941039A1 (de) 2001-03-01
EP1212454A2 (de) 2002-06-12
CA2381952A1 (en) 2001-03-08
WO2001016355A2 (de) 2001-03-08
JP2003508058A (ja) 2003-03-04

Similar Documents

Publication Publication Date Title
EP1140840A4 (de) -g(v)-carboxyaryl substituierte diphenyl harnstoffe als raf kinase inhibitoren
IS2156B (is) Settar bensensúlfonamíðafleiður sem forlyf fyrir COX-2 tálma, aðferð til þess að búa þær til, lyfjasamsetningar sem innihalda þær og notkun þeirra við framleiðslu lyfja
JO2373B1 (en) W-carboxy-aryl diphenyl urease substitutes used as RAV inhibitors
EP1449834A3 (de) Hemmung der RAF-Kinase unter Verwendung von symmetrisch und unsymmetrisch substituierten Harnstoffen
HK1080459A1 (en) Novel pyrimidineamide derivatives and the use thereof
ATE221531T1 (de) Kristallmodifikation des cdch, verfahren zu dessen herstellung und diese enthaltende pharmazeutische zubereitungen
DE69811735T2 (de) Heterocyclische verbindungen zur hemmung der magensäureproduktion, verfahren zu ihrer herstellung und pharmazeutische zubereitungen davon
WO1999054286A3 (en) Btk inhibitors and methods for their identification and use
WO2008028965A3 (en) Inhibitors of protein phosphatase 1, gadd34 and protein phosphatase 1/gadd34 complex, preparation and uses thereof
WO2002040702A3 (en) Methods for the treatment of cancer and other diseases and methods of developing the same
WO2004047792A3 (de) Liposomale glucocorticoide
WO2001074839A3 (en) Methods of making the 4-n-butylcyclohexanoic and the undecanoic acid esters of (7 alpha, 11 beta)-dimethyl-17 beta-hydroxy-4-estren-3-one and their medical use
DE69725860D1 (de) PLAN ZUR VERABREICHUNG VON H+, K+-ATPase INHIBITOREN
DE60301570D1 (de) 1,2,3-substituierte indolizinderivate, fgf inhibitoren, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
ZA945425B (en) 2-amino-4-phenyl-4-oxo-butyric acid derivatives
ZA965969B (en) Salts derived from amidine and cyclooxygenase inhibitor process for the preparation thereof their application as medicinal drugs and pharmaceutical compositions in which they are contained
SE9603725D0 (sv) New teatment
WO2001016355A3 (de) In-vitro-testsystem für gamma-sekretase aus angereicherten-membranen
DE60100500D1 (de) Suspension enthaltend ein epi-hne protein, verfahren zu ihrer herstellung, daraus hergestelltes trockenpulveraerosol, arzneimittelzusammensetzungen enthaltend diese suspension oder dieses aerosol und ihre verwendungen
WO2005002500A3 (en) Inhibitors of coronavirus
IL144199A0 (en) Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
WO2002096870A3 (en) Sponge-derived terpenoids and methods of use
DE59708495D1 (de) Feste instant-release-darreichungsformen und verfahren zu ihrer herstellung
GEP20043286B (en) Dual Inhibitors of Cholesteryl Ester and Wax Ester Synthesis for Sebaceous Gland Disorders
DE69804766D1 (de) Isoflavonderivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP MX US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): CA JP MX US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

WWE Wipo information: entry into national phase

Ref document number: 2000962393

Country of ref document: EP

Ref document number: 2381952

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/001754

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2001 520900

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 10069801

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2000962393

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2000962393

Country of ref document: EP